-

09:12:46 PM

ALGS Stock News

ALGS - Aligos Therapeutics Inc

06/22/22 8:00 AM

Nasdaq : ALGS

clinical triallow float

Aligos Therapeutics Presents 28-Day Safety, Efficacy and Pharmacokinetic Clinical Data for CAM Drug Candidate ALG-000184, First Clinical Data for NASH Drug Candidate ALG-055009 and Nonclinical Data in Other Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s Digital International Liver Congress™ 2022

- Similar significant reductions of hepatitis B virus (HBV) DNA and HBV RNA observed following 28 days of daily oral ALG-000184 dosing, regardless of HBeAg status, across first four dosing chronic hepatitis B (CHB) patient cohorts -In the first clinical data presentation from our NASH program,

RHEA-AI

neutral

06/06/22 8:00 AM

Nasdaq : ALGS

conferenceslow float

Aligos Therapeutics to Participate in Metropolitan AntiViral Drug Accelerator, Recipient of NIH and NIAID Grant to Develop Therapeutics Against Coronaviruses and Pathogens of Pandemic Potential

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company will

RHEA-AI

neutral

05/23/22 4:05 PM

Nasdaq : ALGS

conferenceslow float

Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D.,

RHEA-AI

neutral

05/04/22 4:05 PM

Nasdaq : ALGS

earningslow float

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and

RHEA-AI

neutral

05/03/22 8:00 AM

Nasdaq : ALGS

conferencesclinical triallow float

Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s International Liver Congress™ 2022

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address

RHEA-AI

neutral

04/27/22 4:05 PM

Nasdaq : ALGS

low float

Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the

RHEA-AI

neutral

04/04/22 8:00 AM

Nasdaq : ALGS

covid-19low float

Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19, to Advance into Development

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage

RHEA-AI

neutral

03/22/22 8:00 AM

Nasdaq : ALGS

low float

Aligos Discontinues Development of its Antisense Oligonucleotide Drug Candidate ALG-020572 in Subjects with Chronic Hepatitis B and Pivots Internal Strategic Emphasis to its Small Molecule Portfolio

Dosing in the first cohort discontinued after multiple reports of ALT flares suggestive of drug-induced liver toxicity Funds will be redirected to support ongoing clinical programs, including ALG-000184 (Class-II CAM for CHB) and ALG-055009 (THR- agonist for NASH), and to accelerate internal oral

RHEA-AI

neutral

03/10/22 4:05 PM

Nasdaq : ALGS

earningslow float

Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

CAM (ALG-000184) continues to demonstrate best in class potential in Phase 1b ASO (ALG-020572) completed dosing in Phase 1a (HVs); Phase 1b study (CHB) initiated – 1 st cohort fully enrolled siRNA (ALG-125755) progressing on track through Phase 1 enabling nonclinical studies THR-β (ALG-055009)

RHEA-AI

neutral

03/02/22 4:05 PM

Nasdaq : ALGS

low float

Aligos Therapeutics to Announce Fourth Quarter and Full Year 2021 Results March 10, 2022

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the

RHEA-AI

neutral

1 2 3 4 5 6 Next

ALGS Data

Websitewww.aligos.com
Security nameAligos Therapeutics Inc
Issue typecs
Sic code2836
Employees80
Tags
- Health Technology
- Pharmaceuticals: Major

About Aligos Therapeutics Inc

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.